Cyclerion Therapeutics Q4 2024 Earnings Results & Report

Cyclerion Therapeutics EPS Results

• Actual EPS: $1.54
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Cyclerion Therapeutics Revenue Results

• Actual Revenue: $1.81 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Cyclerion Therapeutics (NASDAQ:KRSA) was a clinical-stage biopharmaceutical company focused on developing medicines for serious diseases involving the central nervous system, cardiovascular system, kidneys and other organs. The company’s research centered on soluble guanylate cyclase stimulators, a class of compounds designed to influence cellular signaling pathways associated with blood flow, inflammation and tissue function.

Cyclerion’s development portfolio historically included IW-6463, an investigational central nervous system therapy, as well as olinciguat and praliciguat, which were studied for potential applications in conditions including neurodegenerative disease, sickle cell disease and diabetic kidney disease. The company was founded in 2019 as a spinout from Ironwood Pharmaceuticals and was headquartered in Cambridge, Massachusetts. Peter Hecht, Ph.D., served as its chief executive officer during a significant portion of its operations.

Public information identifies Cyclerion’s historical Nasdaq trading symbol as CYCN rather than KRSA, and the company’s corporate status and operations may have changed since its period as an independent biotechnology business.